Welcome to our dedicated page for Pulmonx SEC filings (Ticker: LUNG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Pulmonx Corp’s SEC disclosures can feel like navigating a bronchoscopic procedure—essential but intricate. Clinical-trial milestones, FDA post-market study obligations, and global sales data for the Zephyr Endobronchial Valve are scattered across 10-Ks, 10-Qs, and sudden 8-Ks. Investors who simply want to verify safety-event updates or track insider confidence often wade through hundreds of pages.
Stock Titan’s AI-powered analysis extracts what matters. Need the Pulmonx insider trading Form 4 transactions? We surface them in real time, complete with alerts for Pulmonx Form 4 insider transactions real-time and contextual explanations. Looking for the Pulmonx quarterly earnings report 10-Q filing or a Pulmonx annual report 10-K simplified summary? Our algorithms translate dense regulatory language into clear metrics: valve unit growth, reimbursement trends, gross-margin shifts, and R&D spend on next-gen COPD devices. Even sudden developments are covered—Pulmonx 8-K material events explained and linked to market impact. In short, you get Pulmonx SEC filings explained simply.
Every document type is indexed and searchable:
- Proxy statement executive compensation insights
- Underwriting details for debt or equity raises
- Pulmonx earnings report filing analysis you can act on
Amendment No. 2 to Schedule 13D updates insider holdings in TriSalus Life Sciences (TLSI) after the preferred-for-common share exchange completed 31 Jul 2025.
- Mats Wahlstrom now beneficially owns 2,987,881 common shares (6.0% of the class) through Leonard Capital, personal holdings and 157,679 option shares exercisable within 60 days.
- Kerry R. Hicks controls 2,349,795 shares (4.7%) via multiple personal and trust accounts plus 60,596 option shares.
- HW Investment Partners, LLC holds 1,370,028 shares (2.8%). These shares are counted as shared voting/dispositive power for both individuals.
Ownership percentages assume a total of 49,788,874 common shares outstanding, calculated as 37,975,815 shares reported in TLSI’s 13 Jun 2025 Form S-4/A plus 11,813,059 shares issued in the exchange offer.
Leonard Capital converted 50,000 Series A preferred shares for 165,000 common shares at the 3.3-for-1 ratio. Apart from this exchange, no transactions were reported in the past 60 days. The filing is for disclosure only; it does not announce any operational or financial guidance.
FAQ
What is the current stock price of Pulmonx (LUNG)?
What is the market cap of Pulmonx (LUNG)?
What is the core focus of Pulmonx Corp?
What are the key products offered by Pulmonx?
How does the Zephyr Endobronchial Valve work?
What makes Pulmonx's treatment approach unique?
In which markets does Pulmonx operate?
How is clinical evidence integrated into Pulmonx’s strategy?
What are the benefits of Pulmonx's treatment options for patients?
How does Pulmonx maintain its position in the competitive medical technology sector?
